120 related articles for article (PubMed ID: 2169250)
1. Quantitative adaptation of the bacteriophage P4 DNA unknotting assay for use in the biochemical and pharmacological characterization of topoisomerase II.
Hofmann GA; Mirabelli CK; Drake FH
Anticancer Drug Des; 1990 Aug; 5(3):273-82. PubMed ID: 2169250
[TBL] [Abstract][Full Text] [Related]
2. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
[TBL] [Abstract][Full Text] [Related]
3. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage.
Andrea JE; Adachi K; Morgan AR
Mol Pharmacol; 1991 Oct; 40(4):495-501. PubMed ID: 1656189
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of 9-anilinoacridines as inhibitors of human DNA topoisomerase II.
Figgitt DP; Denny WA; Gamage SA; Ralph RK
Anticancer Drug Des; 1994 Jun; 9(3):199-208. PubMed ID: 8031452
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
6. Determination of DNA topoisomerase II activity from L1210 cells--a target for screening antitumor agents.
Wang LG; Liu XM; Ji XJ
Zhongguo Yao Li Xue Bao; 1991 Mar; 12(2):108-14. PubMed ID: 1663690
[TBL] [Abstract][Full Text] [Related]
7. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
8. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells.
Tan KB; Mattern MR; Boyce RA; Hertzberg RP; Schein PS
NCI Monogr; 1987; (4):95-8. PubMed ID: 2819739
[TBL] [Abstract][Full Text] [Related]
9. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
10. Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity.
Habermeyer M; Fritz J; Barthelmes HU; Christensen MO; Larsen MK; Boege F; Marko D
Chem Res Toxicol; 2005 Sep; 18(9):1395-404. PubMed ID: 16167831
[TBL] [Abstract][Full Text] [Related]
11. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
12. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
13. An atypical type II topoisomerase from Mycobacterium smegmatis with positive supercoiling activity.
Jain P; Nagaraja V
Mol Microbiol; 2005 Dec; 58(5):1392-405. PubMed ID: 16313624
[TBL] [Abstract][Full Text] [Related]
14. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.
Woessner RD; Chung TD; Hofmann GA; Mattern MR; Mirabelli CK; Drake FH; Johnson RK
Cancer Res; 1990 May; 50(10):2901-8. PubMed ID: 2159365
[TBL] [Abstract][Full Text] [Related]
15. Rhodobacter capsulatus DNA topoisomerase I purification and characterization.
Alkorta I; Park C; Kong J; Garbisu C; Alberti M; Pon N; Hearst JE
Arch Biochem Biophys; 1999 Feb; 362(1):123-30. PubMed ID: 9917336
[TBL] [Abstract][Full Text] [Related]
16. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
Danks MK; Schmidt CA; Deneka DA; Beck WT
Cancer Commun; 1989; 1(2):101-9. PubMed ID: 2561733
[TBL] [Abstract][Full Text] [Related]
17. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
18. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
[TBL] [Abstract][Full Text] [Related]
19. Analysis of expression and function of topoisomerase I and II during meiosis in male mice.
Cobb J; Reddy RK; Park C; Handel MA
Mol Reprod Dev; 1997 Apr; 46(4):489-98. PubMed ID: 9094096
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
Baloch Z; Cohen S; Coffman FD
J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
